For patients with recurrent ovarian cancer, trebananib did not improve overall survival
the ONA take:
Amgen has announced secondary endpoint results from its TRINOVA-1 study that investigated trebananib plus paclitaxel for the treatment of patients with recurrent ovarian cancer.
The combination therapy did not show a statistically significant improvement in overall survival compared with placebo plus paclitaxel. The TRIANOVA-1 study is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial that evaluated trebananib in combination with weekly paclitaxel in women with epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Researchers randomly assigned patients to receiver either trebananib 15mg/kg intravenously weekly plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles or placebo plus paclitaxel 80mg/m2 intravenously weekly for 3 weeks for 4-week cycles.
Amgen previously announced positive primary endpoint results that showed a statistically significant improvement in progression-free survival in the trebananib group, but secondary endpoint results showed a median overall survival of 19.3 months among those who received trebananib and 18.3 months among those who received placebo.
Despite the disappointing results, trebananib is also being studied in other combinations for the same three cancers. Trebananib is an investigational peptibody that ultimately inhibits angiogenesis, thereby causing cancer cell death.
Results from TRINOVA-1 study that investigated trebananib plus paclitaxel for ovarian cancer.
Amgen today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer.
The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival. Median overall survival was 19.3 months in the trebananib arm versus 18.3 months in the control arm. The data will be submitted to a future medical conference and for publication.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|